FORMA Therapeutics Announces Upcoming Presentations at the 31st Annual Piper Jaffray Healthcare Conference and the 2019 ASH Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--Dec 3, 2019--
FORMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that the company will present at two meetings in December:
FORMA Therapeutics is focused on the discovery, development and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. A fully-integrated biopharmaceutical company, FORMA’s validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates with best-in-class or first-in-class potential. FORMA has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of programs, ranging from preclinical to pivotal-stage, with the potential to provide profound patient benefit. For more information, please visit the company website at www.formatherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191203005156/en/
CONTACT: Investor Contact:
Stephanie Ascher, +1 212-362-1200
Stern Investor Relations
Kari Watson, +1 781-235-3060
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK FLORIDA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: FORMA Therapeutics
Copyright Business Wire 2019.
PUB: 12/03/2019 08:05 AM/DISC: 12/03/2019 08:05 AM